Brigimadlin (BI 907828): A Comprehensive Analysis of a Potent MDM2-p53 Antagonist from Preclinical Promise to Clinical Discontinuation

1.0 Executive Summary

Brigimadlin, also known by its developmental code name BI 907828, is an investigational, orally bioavailable small molecule developed by the pharmaceutical company Boehringer Ingelheim.[1] It was engineered as a highly potent antagonist of the protein-protein interaction between Mouse Double Minute 2 (MDM2) and the tumor suppressor protein p53.[3] The fundamental therapeutic rationale for Brigimadlin was to reactivate the latent tumor-suppressive functions of wild-type p53 in cancers where it is functionally silenced by the overexpression of its primary negative regulator, MDM2. This strategy is particularly relevant for tumor types characterized by amplification of the

MDM2 gene, a genomic alteration that is often mutually exclusive with mutations in the TP53 gene.[4]

Early-phase clinical development was highly encouraging. The first-in-human Phase Ia/Ib study (NCT03449381) established a manageable safety profile, with predictable and reversible on-target toxicities such as thrombocytopenia and neutropenia. The study also demonstrated a favorable pharmacokinetic profile, characterized by a long plasma half-life that supported an intermittent dosing schedule designed to mitigate toxicity. Most importantly, the trial revealed compelling preliminary signs of antitumor activity, particularly in patients with advanced dedifferentiated liposarcoma (DDLPS), a rare cancer with near-universal MDM2 amplification.[3]

These promising results led to the initiation of a broad pivotal program, headlined by the Phase II/III Brightline-1 trial (NCT05218499). This study was designed to compare Brigimadlin directly against the standard-of-care chemotherapy, doxorubicin, in the first-line treatment of advanced DDLPS. However, the trial failed to meet its primary endpoint of demonstrating a statistically significant improvement in progression-free survival (PFS). Despite showing a numerically superior objective response rate, the lack of a significant survival benefit led Boehringer Ingelheim to terminate the global development of Brigimadlin across all indications in early 2025.[6]

This report provides an exhaustive analysis of Brigimadlin, chronicling its journey from a well-founded scientific hypothesis and potent preclinical profile to its ultimate failure in a late-stage clinical setting. It examines the drug's molecular characteristics, its intricate mechanism of action, the full scope of its clinical trial program, and the critical results that led to its discontinuation, placing its story within the broader, challenging landscape of therapies targeting the MDM2-p53 axis.

2.0 Molecular Profile and Physicochemical Characteristics

Brigimadlin is a complex, investigational small molecule drug belonging to the spiro-oxindole chemical class.[1] Compounds in this class have long been recognized as a promising scaffold for inhibiting the MDM2-p53 interaction, though historical efforts were often hampered by issues of chemical stability and suboptimal pharmacokinetic properties. Brigimadlin was the product of a dedicated discovery program aimed at creating a more stable and potent alternative with an improved pharmacokinetic profile suitable for intermittent clinical dosing schedules.[4]

Its formal chemical identity is defined by the International Union of Pure and Applied Chemistry (IUPAC) name (3S,10'S,11'S,14'S)-6-chloro-11'-(3-chloro-2-fluorophenyl)-13'-(cyclopropylmethyl)-6'-methyl-2-oxospiro[1H-indole-3,12'-8,9,13-triazatetracyclo[7.6.0.02,7.010,14]pentadeca-1,3,5,7-tetraene]-5'-carboxylic acid.[8] The molecule is characterized by the chemical formula

C31​H25​Cl2​FN4​O3​, with an average molecular weight of 591.46 g/mol and a monoisotopic mass of 590.1287742 Da.[8]

The drug is known by several identifiers used across scientific literature, regulatory filings, and chemical databases. Its primary developmental code name is BI 907828, and it is registered under CAS Number 2095116-40-6 and DrugBank Accession Number DB18578.[8]

The physicochemical properties of Brigimadlin are critical to understanding its behavior as a drug. With a calculated logarithm of the partition coefficient (logP) of 4.7, the molecule is highly lipophilic, a characteristic that often facilitates cell membrane permeability but can also present challenges for aqueous solubility.[9] Indeed, experimental data confirm that Brigimadlin is insoluble in water but highly soluble in organic solvents such as dimethyl sulfoxide (DMSO) and ethanol, where it can reach concentrations of 100 mg/mL.[11] Its acid-base properties are defined by a strongest acidic pKa of 3.32 (attributed to the carboxylic acid group) and a strongest basic pKa of 5.03, resulting in a net physiological charge of -1 at a pH of 7.4.[9] These characteristics, along with its polar surface area of 87.46 Ų and four rotatable bonds, influence its absorption, distribution, metabolism, and excretion (ADME) profile. For clinical administration, Brigimadlin was formulated as an oral tablet.[3] The comprehensive identification and physicochemical properties are summarized in Table 1.

Table 1: Summary of Brigimadlin Identification and Physicochemical Properties

Property	Value	Source(s)
Identifiers
Generic Name	Brigimadlin	8
DrugBank ID	DB18578	8
CAS Number	2095116-40-6	8
Developmental Code	BI 907828	3
Structural Data
Chemical Formula	C31​H25​Cl2​FN4​O3​	8
Average Weight	591.46 g/mol	9
Monoisotopic Weight	590.1287742 Da	8
Physicochemical Properties
logP	4.7	9
pKa (Strongest Acidic)	3.32	9
pKa (Strongest Basic)	5.03	9
Physiological Charge	-1	9
Hydrogen Acceptor Count	5	9
Hydrogen Donor Count	2	9
Polar Surface Area	87.46 Ų	9
Rotatable Bond Count	4	9
Solubility
Water	Insoluble	11
DMSO	100 mg/mL (169.07 mM)	11
Ethanol	100 mg/mL	11

3.0 Pharmacological Rationale: Targeting the MDM2-p53 Axis

3.1 The p53 Tumor Suppressor: "Guardian of the Genome"

The therapeutic strategy behind Brigimadlin is rooted in the central role of the p53 protein in cancer biology. Encoded by the TP53 gene, p53 is a transcription factor often referred to as the "guardian of the genome" due to its critical function in maintaining cellular and genetic stability.[4] In response to various forms of cellular stress, including DNA damage, oncogene activation, or hypoxia, the p53 pathway is activated. This activation leads to the stabilization of the p53 protein, allowing it to orchestrate a range of cellular responses, most notably cell cycle arrest to allow for DNA repair, cellular senescence, or, in cases of irreparable damage, apoptosis (programmed cell death).[3]

The loss of p53 function is a near-universal hallmark of human cancer, enabling cells to evade these crucial protective mechanisms and promoting unchecked proliferation and survival.[3] This inactivation occurs through one of two principal routes: direct mutation of the

TP53 gene, which occurs in approximately half of all tumors, or functional silencing of the wild-type p53 protein by other cellular mechanisms.[4]

3.2 MDM2: The Key Negative Regulator of p53

In cells with wild-type TP53, the activity and stability of the p53 protein are tightly controlled by its primary negative regulator, the Mouse Double Minute 2 homolog (MDM2) oncoprotein.[4] MDM2 is itself a transcriptional target of p53, forming a classic negative feedback loop that ensures p53 levels are kept low in unstressed cells.[15] MDM2 exerts its inhibitory effect through two distinct but complementary mechanisms. First, it binds directly to the N-terminal transactivation domain of p53, physically obstructing p53's ability to bind to the promoter regions of its target genes and initiate transcription.[8] Second, and more critically, MDM2 functions as an E3 ubiquitin ligase. It attaches ubiquitin molecules to p53, marking it for degradation by the cellular proteasome.[10] This constant degradation ensures that p53 protein levels remain low and its tumor-suppressive functions are held in check under normal physiological conditions.

3.3 The Therapeutic Hypothesis: Reactivating p53 in MDM2-Amplified Cancers

The discovery that a subset of human cancers circumvents p53 function not by mutating TP53 but by amplifying the MDM2 gene provided a compelling therapeutic opportunity.[3]

MDM2 amplification, which occurs in approximately 3.5% to 7% of all tumors, leads to massive overexpression of the MDM2 protein.[3] This excess MDM2 effectively sequesters and degrades any wild-type p53 protein, leading to its complete functional inactivation.[5]

This molecular context is particularly prevalent in specific cancer types, such as dedifferentiated liposarcoma (DDLPS), where MDM2 amplification is found in over 90% of cases.[16] Crucially,

MDM2 amplification and TP53 mutations are almost always mutually exclusive events; a tumor has no evolutionary pressure to acquire a TP53 mutation if it has already silenced p53 via MDM2 overexpression.[4] This creates a distinct molecular subtype of cancer that is highly dependent on the MDM2-p53 interaction for its survival. The therapeutic hypothesis is therefore direct and elegant: in an

MDM2-amplified, TP53 wild-type tumor, a small molecule that can physically disrupt the MDM2-p53 interaction should liberate p53 from its negative regulator. This would lead to the rapid stabilization and activation of wild-type p53, selectively triggering apoptosis or cell cycle arrest in the cancer cells while having a lesser effect on normal cells with balanced MDM2-p53 levels.[3]

3.4 Brigimadlin's Mechanism of Action and Preclinical Evidence

Brigimadlin was designed to execute this therapeutic strategy with high potency and optimized drug-like properties.[4] X-ray co-crystal structures confirmed that Brigimadlin binds with high affinity to the deep hydrophobic p53-binding pocket on the surface of the MDM2 protein.[7] By occupying this pocket, it physically prevents MDM2 from engaging with p53, thereby breaking the inhibitory interaction.[8]

Preclinical studies robustly validated this mechanism. In biochemical assays, Brigimadlin demonstrated superior potency in inhibiting the MDM2-p53 interaction, with a half-maximal inhibitory concentration (IC50​) of 2 nM, which was more potent than earlier molecules from the same chemical series.[7] In

TP53 wild-type cancer cell lines, treatment with Brigimadlin led to the expected biological consequences of p53 reactivation. It caused a dose-dependent accumulation of p53 protein and induced the transcription of canonical p53 target genes, such as CDKN1A (encoding the cell cycle inhibitor p21) and PUMA (encoding a pro-apoptotic protein).[7] This translated into potent anti-proliferative and pro-apoptotic activity, with Brigimadlin inhibiting the viability of cancer cells at nanomolar concentrations.[10] Sensitivity to Brigimadlin across large cancer cell line panels correlated strongly with both

TP53 wild-type status and MDM2 amplification, confirming the biomarker-driven hypothesis.[7]

This in vitro activity was successfully translated into in vivo models. Oral administration of Brigimadlin resulted in potent, single-agent tumor growth inhibition and regression in multiple xenograft models of TP53 wild-type, MDM2-amplified cancers, with particularly strong activity observed in DDLPS patient-derived xenografts.[3]

A critical aspect of Brigimadlin's design was its pharmacokinetic profile. The restoration of p53 function is a powerful biological event that affects not only cancer cells but also normal, rapidly proliferating tissues, particularly hematopoietic stem cells in the bone marrow.[4] This leads to the primary on-target, dose-limiting toxicities for the MDM2 inhibitor class: thrombocytopenia (low platelets) and neutropenia (low neutrophils).[3] Brigimadlin was engineered to have a long plasma elimination half-life, a property that would enable intermittent dosing schedules (e.g., a single dose every 21 days). The rationale for this design was to provide a sufficiently long drug-free interval between doses to allow for the recovery of normal bone marrow function, thereby widening the therapeutic window and improving the overall tolerability of the drug in patients.[4]

4.0 The Clinical Development Program of Brigimadlin

4.1 First-in-Human Studies: The Phase Ia/Ib Trial (NCT03449381)

The clinical journey of Brigimadlin began with NCT03449381, a first-in-human, open-label, multicenter study designed to evaluate the drug's safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity in patients with advanced or metastatic solid tumors.[3] The Phase Ia dose-escalation portion enrolled 54 patients and explored two different intermittent dosing schedules: a single oral dose on day 1 of a 21-day cycle (D1q3w) and doses on days 1 and 8 of a 28-day cycle (D1D8q4w).[3]

The safety profile observed in this initial study was consistent with the drug's mechanism of action. The most frequently reported treatment-related adverse events (TRAEs) were gastrointestinal, primarily nausea (74.1%) and vomiting (51.9%), which were generally manageable with standard antiemetic prophylaxis.[3] The most common grade

≥3 TRAEs were the anticipated on-target hematologic toxicities: thrombocytopenia (25.9%) and neutropenia (24.1%).[3] These events were dose-dependent and reversible, aligning with the strategy of using an intermittent schedule to allow for bone marrow recovery. Based on the incidence of dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) for the q3w schedule was determined to be 60 mg, and the recommended dose for expansion (RDE) for subsequent studies was selected as 45 mg q3w.[3]

Pharmacokinetic analyses in patients confirmed the favorable profile observed in preclinical models. Brigimadlin demonstrated high systemic exposure and a long plasma elimination half-life of 30-60 hours, validating the feasibility of the once-every-three-weeks dosing regimen.[3] Furthermore, target engagement was demonstrated through pharmacodynamic markers; treatment with Brigimadlin led to time- and dose-dependent increases in plasma levels of Growth Differentiation Factor 15 (GDF-15), a known transcriptional target of p53, providing clear evidence that the drug was successfully activating the p53 pathway in patients.[3]

Most encouragingly, the study yielded strong preliminary signals of clinical efficacy. Across all patients, the overall response rate was 11.1%, and the disease control rate (DCR), which includes responses and stable disease, was 74.1%.[3] The activity was particularly striking in the subset of patients with

MDM2-amplified liposarcoma, the tumor type with the strongest biological rationale for this therapy. In this group, the DCR was 100% for patients with well-differentiated liposarcoma (WDLPS) and 75% for those with dedifferentiated liposarcoma (DDLPS).[3] Later analyses of the expanded DDLPS cohort (n=69) from the Phase Ib portion confirmed this promise, showing an objective response rate (ORR) of 14.5%, a DCR of 82.6%, and a preliminary median progression-free survival (PFS) of 7.9 months.[23]

4.2 The "Brightline" Pivotal Program: A Biomarker-Driven Strategy

The robust efficacy signal in MDM2-amplified tumors, especially DDLPS, provided a clear path forward for late-stage development. Boehringer Ingelheim launched a comprehensive clinical program under the "Brightline" moniker, focusing specifically on patient populations selected by the MDM2 amplification biomarker.[5] This program was designed to definitively assess the clinical benefit of Brigimadlin in these targeted indications. The key trials in this program are summarized in Table 2.

Table 2: Overview of Key Clinical Trials for Brigimadlin

Trial Identifier	Phase	Primary Indication(s)	Key Intervention(s)	Status (as of early 2025)	Source(s)
NCT03449381	Ia/Ib	Advanced Solid Tumors	Brigimadlin Monotherapy	Active, Not Recruiting	3
NCT05218499 (Brightline-1)	II/III	Advanced Dedifferentiated Liposarcoma (DDLPS) (1st Line)	Brigimadlin vs. Doxorubicin	Completed (Failed Primary Endpoint)	6
NCT05512377 (Brightline-2)	IIa/IIb	Biliary Tract, Pancreatic, Lung, Bladder Cancer (2nd Line)	Brigimadlin Monotherapy	Terminated	12
NCT06058793 (Brightline-4)	III	Advanced DDLPS	Brigimadlin Monotherapy	On Hold / Terminated	12
NCT03964233	I	Advanced Solid Tumors	Brigimadlin + Ezabenlimab (anti-PD-1)	Active, Not Recruiting	12
NCT05376800	0/Ia	Newly Diagnosed Glioblastoma	Brigimadlin + Radiotherapy	Recruiting	12

The Brightline-2 trial (NCT05512377) was a Phase IIa/IIb study designed to evaluate Brigimadlin as a second-line treatment for patients with other MDM2-amplified advanced cancers, including biliary tract cancer (BTC), pancreatic ductal adenocarcinoma (PDAC), lung adenocarcinoma, and bladder cancer.[24] The Brightline-4 trial (NCT06058793) was a planned Phase III single-arm study to further assess Brigimadlin in advanced DDLPS.[28] However, the fate of the entire program hinged on the results of its flagship study, Brightline-1.

5.0 Pivotal Trial Failure and Program Termination

5.1 The Brightline-1 Study (NCT05218499): The Decisive Trial

The Brightline-1 study was the pivotal trial designed to secure regulatory approval for Brigimadlin. It was a large, randomized, open-label, multicenter Phase II/III trial that directly compared Brigimadlin (administered at the RDE of 45 mg orally once every three weeks) against the established first-line standard of care, doxorubicin, in patients with advanced or metastatic DDLPS.[25] The primary endpoint of the study was progression-free survival (PFS), as assessed by blinded independent central review.[6]

5.2 Analysis of the Topline Results

In late 2024, Boehringer Ingelheim announced the topline results from Brightline-1, which proved to be definitive and disappointing. The study failed to meet its primary endpoint. While there was a numerical trend favoring Brigimadlin, the difference in PFS compared to doxorubicin was not statistically significant, with a hazard ratio of 0.79 and a p-value of 0.0956.[6]

This outcome presented a critical paradox. Analysis of a key secondary endpoint, objective response rate (ORR), showed that Brigimadlin was numerically superior to doxorubicin, inducing tumor shrinkage in 22.3% of patients compared to just 8.6% in the doxorubicin arm (Odds Ratio 2.93).[34] However, because the study's statistical analysis plan was hierarchical, the failure to achieve significance on the primary endpoint of PFS meant that this difference in ORR could not be formally claimed as a statistically significant finding.[34]

The discordance between a higher rate of tumor shrinkage and the lack of a significant survival benefit is a crucial finding. It suggests that while Brigimadlin was more effective at inducing an initial response, these responses may not have been sufficiently durable to translate into a longer period of disease control. Several factors could contribute to this outcome. It is possible that tumors developed resistance to p53-mediated apoptosis relatively quickly. Alternatively, the cumulative toxicity of the agent, even with intermittent dosing, may have necessitated dose reductions or delays over time, potentially compromising its long-term efficacy. Regardless of the underlying cause, the result demonstrated that a higher ORR did not serve as a reliable surrogate for a meaningful PFS benefit in this context, a critical lesson for the development of drugs with this mechanism of action.

5.3 Corporate Decision: Termination of the Brigimadlin Program

The failure of the Brightline-1 trial to meet its primary endpoint was a decisive blow to the program. In early 2025, a spokesperson for Boehringer Ingelheim confirmed that the company had made the strategic decision to terminate the development of Brigimadlin across all indications.[6] This was further evidenced by the withdrawal of planned combination studies, such as Brightline-3, from clinical trial registries and the halting of other ongoing trials.[6] The outcome of this single pivotal study effectively ended a decade of research and substantial investment into what was once considered one of the company's most advanced oncology assets.[6]

6.0 Regulatory Context and Competitive Landscape

6.1 Regulatory Designations: A Sign of Initial Promise

Prior to the pivotal trial failure, Brigimadlin had garnered positive attention from regulatory agencies, reflecting the significant unmet need in the diseases it targeted and the strength of its early data. In the United States, the Food and Drug Administration (FDA) granted Brigimadlin Fast Track Designation for the treatment of DDLPS.[17] This designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Furthermore, Brigimadlin received

Orphan Drug Designation from both the FDA for liposarcoma and the European Medicines Agency (EMA) for soft tissue sarcoma.[1] This status provides various development incentives, including market exclusivity, for therapies targeting rare diseases. These designations highlighted the initial regulatory optimism for Brigimadlin's potential to become a meaningful new therapy.

6.2 The Challenging Landscape of MDM2 Inhibitors: A Pattern of Failure

Brigimadlin's discontinuation is not an anomaly but rather a reflection of the profound and persistent challenges in therapeutically targeting the MDM2-p53 axis. The history of this drug class is replete with promising candidates that ultimately failed in late-stage development, suggesting a class-wide difficulty in balancing on-target efficacy with on-target toxicity.[6]

A striking parallel can be drawn with milademetan (RAIN-32), another potent, selective MDM2 inhibitor. Similar to Brigimadlin, milademetan showed encouraging single-agent activity in a Phase I study, particularly in patients with DDLPS.[39] This led to the launch of its own pivotal Phase III trial, MANTRA, which compared milademetan to the chemotherapy agent trabectedin in patients with advanced DDLPS who had progressed on prior therapy.[41] In May 2023, Rain Oncology announced that the MANTRA trial had also failed to meet its primary endpoint of improving PFS.[43] The parallel failures of two different potent MDM2 inhibitors in randomized Phase III trials in the same rare cancer underscore that the issue likely transcends any single molecule's specific properties and points to a more fundamental challenge with the therapeutic strategy.

This pattern extends to several other agents from major pharmaceutical companies, including idasanutlin (Roche), siremadlin (Novartis), and SAR405838 (Sanofi), all of which were discontinued during clinical development.[6] The consistent theme appears to be an unfavorable therapeutic index. The dose required to achieve durable, meaningful tumor regression may be too close to the dose that causes chronic and clinically significant myelosuppression, making sustained treatment untenable for many patients.

6.3 The Next Generation: Emerging Strategies

Despite these setbacks, research into targeting the MDM2-p53 pathway continues, albeit with evolving strategies.

• Navtemadlin (KRT-232): Developed by Kartos Therapeutics, this MDM2 inhibitor is being pursued in a different disease context. Its lead indication is myelofibrosis, a hematologic malignancy, where it is being evaluated primarily as an add-on therapy to JAK inhibitors in the Phase III POIESIS study (NCT06479135).[46] This combination approach may allow for synergistic activity or enable lower, more tolerable doses of the MDM2 inhibitor.
• MDM2 Degraders (e.g., KT-253): A novel approach has emerged with the development of targeted protein degraders. Molecules like KT-253, developed by Kymera Therapeutics, are heterobifunctional compounds designed not just to block MDM2's function but to induce its complete degradation and elimination by the cell's proteasomal machinery.[49] The scientific rationale for this approach is that degradation may overcome the feedback loop where MDM2 inhibition leads to increased MDM2 protein expression, potentially resulting in a more profound and durable p53 activation. Early clinical data for KT-253 have shown signs of efficacy in both solid and liquid tumors without the severe hematologic toxicities seen with traditional inhibitors, suggesting it may possess a superior therapeutic window.[50]

7.0 Conclusion and Future Perspectives

Brigimadlin represents a case study in modern, rational drug design. It was a highly potent and selective MDM2-p53 antagonist with an optimized pharmacokinetic profile specifically engineered to address the known tolerability challenges of its therapeutic class. The drug successfully demonstrated its intended biological mechanism in humans, confirming target engagement and producing compelling antitumor activity in biomarker-selected patients during early-phase trials.

However, the ultimate failure of the pivotal Brightline-1 trial underscores the critical and often unpredictable gap between promising early-phase data and late-stage clinical success. The inability of Brigimadlin to translate a superior objective response rate into a statistically significant progression-free survival benefit in DDLPS serves as a profound cautionary tale. It suggests that for this class of agents, transient tumor shrinkage may not be a reliable surrogate for durable disease control, and highlights the immense challenge of achieving a favorable balance between efficacy and on-target toxicity.

The story of Brigimadlin, when viewed alongside the parallel failure of milademetan and the discontinuation of numerous other MDM2 inhibitors, strongly indicates that the single-agent therapeutic strategy for this class may be fundamentally flawed for the treatment of advanced solid tumors. The therapeutic window appears to be intrinsically narrow, where the doses required for sustained efficacy are inseparable from those causing clinically significant myelosuppression.

While the development of Brigimadlin has been terminated, the extensive data generated from its comprehensive clinical program provide invaluable lessons for the oncology community. The future of therapeutically targeting this cornerstone of cancer biology may lie not in simple inhibition, but in more nuanced strategies. These could include rational combination therapies that synergize with p53 reactivation, the identification of novel biomarkers to pinpoint patient populations with exceptional sensitivity, or the advancement of next-generation modalities, such as targeted protein degradation, that may finally unlock a wider and more manageable therapeutic window. Brigimadlin's journey, though ending in disappointment, has significantly informed the path forward in the quest to drug the "undruggable" p53 pathway.

Works cited

1. Brigimadlin - Boehringer Ingelheim - AdisInsight - Springer, accessed September 29, 2025, https://adisinsight.springer.com/drugs/800051467
2. Brigimadlin by Boehringer Ingelheim International for Dedifferentiated Liposarcoma: Likelihood of Approval - Pharmaceutical Technology, accessed September 29, 2025, https://www.pharmaceutical-technology.com/data-insights/brigimadlin-boehringer-ingelheim-international-dedifferentiated-liposarcoma-likelihood-of-approval/
3. The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10401071/
4. Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11612618/
5. Brigimadlin mechanism of action in MDM2-amplified, TP53 wild-type tumor... | Download Scientific Diagram - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/figure/Brigimadlin-mechanism-of-action-in-MDM2-amplified-TP53-wild-type-tumor-cells-MDM2_fig1_377357693
6. Another false dawn for p53 | ApexOnco - Clinical Trials news and analysis, accessed September 29, 2025, https://www.oncologypipeline.com/apexonco/another-false-dawn-p53
7. Brigimadlin, a Novel and Potent MDM2–p53 Antagonist - AACR Journals, accessed September 29, 2025, https://aacrjournals.org/mct/article-pdf/doi/10.1158/1535-7163.MCT-23-0783/3497151/mct-23-0783.pdf
8. Brigimadlin | C31H25Cl2FN4O3 | CID 129264140 - PubChem, accessed September 29, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Brigimadlin
9. Brigimadlin: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 29, 2025, https://go.drugbank.com/drugs/DB18578
10. Brigimadlin (BI 907828) | MDM-2 Inhibitor - MedchemExpress.com, accessed September 29, 2025, https://www.medchemexpress.com/brigimadlin.html
11. Brigimadlin | MDM2/MDMX inhibitor | Mechanism | Concentration - Selleck Chemicals, accessed September 29, 2025, https://www.selleckchem.com/products/brigimadlin.html
12. MDM2-p53 Antagonist-brigimadlin | InOncology - Boehringer Ingelheim, accessed September 29, 2025, https://pro.boehringer-ingelheim.com/us/inoncology/our-pipeline/mdm2-p53-antagonist
13. Brigimadlin - GlpBio, accessed September 29, 2025, https://www.glpbio.com/brigimadlin.html
14. Discovery and structure of brigimadlin. A, Development of brigimadlin.... - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/figure/Discovery-and-structure-of-brigimadlin-A-Development-of-brigimadlin-B-X-ray_fig1_383952070
15. Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2/MdmX Interaction, accessed September 29, 2025, https://www.mdpi.com/2073-4409/14/8/583
16. The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study | Cancer Discovery - AACR Journals, accessed September 29, 2025, https://aacrjournals.org/cancerdiscovery/article/13/8/1802/728135/The-MDM2-p53-Antagonist-Brigimadlin-BI-907828-in
17. 145 Tumour cells - Boehringer Ingelheim, accessed September 29, 2025, https://content.boehringer-ingelheim.com/DAM/1f195a0a-4d49-4bff-a5be-b0ab0103e57d/brigimadlin%201403.1%20ctos%202023%20infographic.pdf
18. BI-907828 (Brigimadlin) - Chemietek, accessed September 29, 2025, https://www.chemietek.com/bi-907828--brigimadlin-details.aspx
19. Brigimadlin | CAS#2095116-40-6 | Mdm2 inhibitor - MedKoo Biosciences, accessed September 29, 2025, https://www.medkoo.com/products/52803
20. Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose Schedules - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/39259562/
21. Study Details | NCT03449381 | This Study Aims to Find the Best ..., accessed September 29, 2025, https://clinicaltrials.gov/study/NCT03449381
22. A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors, accessed September 29, 2025, https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2022-0083.html
23. Brigimadlin-Results | InOncology – Boehringer Ingelheim, accessed September 29, 2025, https://pro.boehringer-ingelheim.com/us/inoncology/our-pipeline/mdm2-p53-antagonist/brigimadlin-results
24. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in ..., accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/38214149/
25. Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/36987836/
26. Study Details | NCT05218499 | Brightline-1: A Study to Compare ..., accessed September 29, 2025, https://clinicaltrials.gov/study/NCT05218499
27. Brigimadlin Active Not Recruiting Phase 2 Trials for Bile Duct Cancer / Pancreatic Neoplasms / Lung Neoplasm Treatment - DrugBank, accessed September 29, 2025, https://go.drugbank.com/drugs/DB18578/clinical_trials?conditions=DBCOND0032251%2CDBCOND0029085%2CDBCOND0028305&phase=2&purpose=treatment&status=active_not_recruiting
28. Brigimadlin Active Not Recruiting Phase 3 Trials for Dedifferentiated Liposarcoma Treatment, accessed September 29, 2025, https://go.drugbank.com/drugs/DB18578/clinical_trials?conditions=DBCOND0044623&phase=3&purpose=treatment&status=active_not_recruiting
29. Efficacy and Safety of Brigimadlin (BI 907828) in Patients With Advanced BTC: Data From 2 Phase 1a/1b Dose-Escalation/Expansion Trials | CCA News Online, accessed September 29, 2025, https://ccanewsonline.com/issues/2024/march-2024-vol-5-no-1/efficacy-and-safety-of-brigimadlin-bi-907828-in-patients-with-advanced-btc-data-from-2-phase-1a-1b-dose-escalation-expansion-trials
30. Efficacy and safety of brigimadlin (BI 907828), an MDM2–p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials. - ASCO Publications, accessed September 29, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.487
31. A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma - National Cancer Institute, accessed September 29, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-09118
32. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors - PMC - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11721627/
33. Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naïve or pre-treated advanced dedifferentiated liposarcoma | Dana-Farber Cancer Institute, accessed September 29, 2025, https://www.dana-farber.org/clinical-trials/24-245
34. brigimadlin versus standard-of-care doxorubicin as first-line treatment in patients with advanced dedifferentiated liposarcoma: brightline-1 - Boehringer Ingelheim, accessed September 29, 2025, https://content.boehringer-ingelheim.com/DAM/d878f419-22f3-448c-8aba-b23d00cdef16/ctos%202024%20oral%20presentation%20brigimadlin%20sch%C3%B6ffski.pdf
35. With 2 planned launches, Boehringer Ingelheim looks to make a name for itself in oncology, accessed September 29, 2025, https://www.fiercepharma.com/pharma/asco-boehringer-ingelheim-make-name-oncology-two-upcoming-launches
36. Brigimadlin: A Novel MDM2-Targeted Therapy for Dedifferentiated Liposarcoma, accessed September 29, 2025, https://www.pharmacytimes.com/view/brigimadlin-a-novel-mdm2-targeted-therapy-for-dedifferentiated-liposarcoma
37. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future, accessed September 29, 2025, https://researchexperts.utmb.edu/en/publications/mdm2-inhibitors-for-cancer-therapy-the-past-present-and-future
38. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future - PMC - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11068841/
39. MDM2 Inhibition Marches on Across Cancer Settings | Targeted Oncology, accessed September 29, 2025, https://www.targetedonc.com/view/mdm2-inhibition-marches-on-across-cancer-settings
40. A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas - ASCO Publications, accessed September 29, 2025, https://ascopubs.org/doi/10.1200/JCO.22.01285
41. Press Release: Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma, accessed September 29, 2025, https://www.rainoncology.com/news-press-releases/rain-therapeutics-announces-completion-of-enrollment-in-phase-3-mantra-trial-for-milademetan-in-liposarcoma
42. Study Details | NCT04979442 | Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma | ClinicalTrials.gov, accessed September 29, 2025, https://www.clinicaltrials.gov/study/NCT04979442
43. Press Release: Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma, accessed September 29, 2025, https://www.rainoncology.com/news-press-releases/rain-oncology-announces-topline-results-from-phase-3-mantra-trial-of-milademetan-for-the-treatment-of-dedifferentiated-liposarcoma
44. Milademetan Does Not Improve Survival Vs Trabectedin in Liposarcoma | CancerNetwork, accessed September 29, 2025, https://www.cancernetwork.com/view/milademetan-does-not-improve-survival-vs-trabectedin-in-liposarcoma
45. Rain Oncology's Milademetan Fails in Phase 3 Trial in Dedifferentiated Liposarcoma, accessed September 29, 2025, https://globalgenes.org/raredaily/rain-oncologys-milademetan-fails-in-phase-3-trial-in-dedifferentiated-liposarcoma/
46. Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib - NCI, accessed September 29, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-05880
47. NCT06479135 | Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | ClinicalTrials.gov, accessed September 29, 2025, https://www.clinicaltrials.gov/study/NCT06479135
48. Navtemadlin Shows Efficacy, Safety in Relapsed/Refractory Myelofibrosis - CancerNetwork, accessed September 29, 2025, https://www.cancernetwork.com/view/navtemadlin-shows-efficacy-safety-in-relapsed-refractory-myelofibrosis
49. Novel MDM2 Degrader KT-253 Receives FDA Orphan Drug Designation In AML, accessed September 29, 2025, https://www.cancernetwork.com/view/novel-mdm2-degrader-kt-253-receives-fda-orphan-drug-designation-in-aml
50. Kymera Therapeutics Shares Phase 1 Trial Data on MDM2 Degrader KT-253 at ASCO, accessed September 29, 2025, https://synapse.patsnap.com/article/kymera-therapeutics-shares-phase-1-trial-data-on-mdm2-degrader-kt-253-at-asco
51. KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors | Molecular Cancer Therapeutics - AACR Journals, accessed September 29, 2025, https://aacrjournals.org/mct/article/24/4/497/754280/KT-253-a-Novel-MDM2-Degrader-and-p53-Stabilizer
52. Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting, accessed September 29, 2025, https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-presents-new-clinical-data-ongoing-phase-1/
53. New clinical data being presented at the ASCO from our ongoing KT-253 Phase 1 oncology trial - Kymera Therapeutics - OncoDaily, accessed September 29, 2025, https://oncodaily.com/blog/76302